The two main aims of this clinical study is;
1. To investigate if the results from a series of physiological tests and questionnaires prior to treatment, can be used to predict the treatment response to obesity medication
2. To investigate the effect of combining semaglutide and pramlintide on various aspects of appetite, food preference and eating habits.
The study is planed as a 26 week, double blinded, randomized, placebo controlled trial. The goal is to include N=40. They will all receive weekly semaglutide injections. After 24 weeks they will be randomized to receive either an amylin analog (pramlintide) or placebo as a continuous infusion for two weeks, in addition to weekly semaglutide.
The results from this study will contribute to identifying possible predictors of treatment response, enabling optimal individualized medical weight loss treatment. As well as providing knowledge on the complex interplay between incretin hormones and their effects on appetite and eating habits.

Start Date01 Sep 2025

Sponsor / Collaborator-

NCT06186063

/ RecruitingNot ApplicableIIT

The Role of Amylin in Bone Metabolism

The clinical study aims to investigate the effect of the intravenously administrated amylin analogue (pramlintide) on the circulating levels of C-terminal telopeptide of type I collagen (CTX-1) (a marker of bone resorption) and N-terminal propeptide of type I procollagen (P1NP) (a marker of bone formation) in individuals with type 1 diabetes and matched healthy controls during fasting euglycemic conditions.

Start Date12 Feb 2024

Sponsor / Collaborator-

NCT06046417

/ RecruitingPhase 2/3IIT

A Randomized, Controlled, Crossover Trial to Assess a Fully Automated, Dual-hormone (Insulin-and-pramlintide) Delivery System Without Carbohydrate Counting in Regulating Glucose Levels in Adults With Type 1 Diabetes.

The aim of this clinical trial is to investigate whether a fully automated Lyumjev-and-pramlintide delivery system improves glycemic outcomes in adults with type 1 diabetes. The main question we aim to answer is whether a Lyumjev-pramlintide fully closed loop system improves time in range compared to a hybrid closed loop system with carbohydrate counting. We also aim to find the optimal insulin to pramlintide ratio for glycemic control in the fully automated system.
In this cross-over study, patients will undergo the following three interventions in a random order:
(i) fully automated Lyumjev insulin-and-pramlintide (8 μg/u) (ii) fully automated Lyumjev insulin-and-pramlintide (10 μg/u) (iii) rapid automated Lyumjev insulin-and-placebo with carbohydrate-matched boluses
For all interventions, participants will be required to wear two Ypsomed pumps programmed by our developed EuGlide system.

Start Date30 Nov 2023

Sponsor / Collaborator

McGill University Health Centre

[+1]

100 Clinical Results associated with Pramlintide Acetate

100 Translational Medicine associated with Pramlintide Acetate

100 Patents (Medical) associated with Pramlintide Acetate

411

Literatures (Medical) associated with Pramlintide Acetate

01 Jun 2025·Diabetes Therapy

Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity

Review

Author: Janež, Andrej ; Muzurović, Emir ; Koceva, Andrijana ; Jensterle, Mojca ; Volčanšek, Špela

Precision diabetology is increasingly becoming diabetes phenotype-driven, whereby the specific hormonal imbalances involved are taken into consideration. Concomitantly, body weight-favorable therapeutic approaches are being dictated by the obesity pandemic, which extends to all diabetes subpopulations. Amylin, an anorexic neuroendocrine hormone co-secreted with insulin, is deficient in individuals with diabetes and plays an important role in postprandial glucose homeostasis, with additional potential cardiovascular and neuroprotective functions. Its actions include suppressing glucagon secretion, delaying gastric emptying, increasing energy expenditure and promoting satiety. While amylin holds promise as a therapeutic agent, its translation into clinical practice is hampered by complex receptor biology, the limitations of animal models, its amyloidogenic properties and pharmacokinetic challenges. In individuals with advanced β-cell dysfunction, supplementing insulin therapy with pramlintide, the first and currently only approved injectable short-acting selective analog of amylin, has demonstrated efficacy in enhancing both postprandial and overall glycemic control in both type 2 diabetes (T2D) and type 1 diabetes (T1D) without increasing the risk of hypoglycemia or weight gain. Current research focuses on several key strategies, from enhancing amylin stability by attaching polyethylene glycol or carbohydrate molecules to amylin, to developing oral amylin formulations to improve patients' convenience, as well as developing various combination therapies to enhance weight loss and glucose regulation by targeting multiple receptors in metabolic pathways. The novel synergistically acting glucagon-like peptide-1 (GLP-1) receptor agonist combined with the amylin agonist, CagriSema, shows promising results in both glucose regulation and weight management. As such, amylin agonists (combined with other members of the incretin class) could represent the elusive drug candidate to address the multi-hormonal dysregulations of diabetes subtypes and qualify as a precision medicine approach that surpasses the long overdue division into T1DM and T2DM. Further development of amylin-based therapies or delivery systems is crucial to fully unlock the therapeutic potential of this intriguing hormone.Graphical abstract available for this article.

09 May 2025·ENDOCRINE REVIEWS

Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance

Review

Author: Lambadiari, Vaia ; Dimitriadis, George D ; Roden, Michael ; Apostolopoulou, Maria

Abstract:

People with type 1 diabetes (T1D) are usually considered to exclusively exhibit β-cell failure, but they frequently also feature insulin resistance. This review discusses the mechanisms, clinical features, and therapeutic relevance of insulin resistance by focusing mainly on human studies using gold-standard techniques (euglycemic–hyperinsulinemic clamp). In T1D, tissue-specific insulin resistance can develop early and sustain throughout disease progression. The underlying pathophysiology is complex, involving both metabolic- and autoimmune-related factors operating synergistically. Insulin treatment may play an important pathogenic role in predisposing individuals with T1D to insulin resistance. However, the established lifestyle-related risk factors and peripheral insulin administration inducing glucolipotoxicity, hyperinsulinemia, hyperglucagonemia, inflammation, mitochondrial abnormalities, and oxidative stress cannot always fully explain insulin resistance in T1D, suggesting a phenotype distinct from type 2 diabetes. The mutual interaction between insulin resistance and impaired endothelial function further contributes to diabetes-related complications. Insulin resistance should therefore be considered a treatment target in T1D. Aside from lifestyle modifications, continuous subcutaneous insulin infusion can ameliorate insulin resistance and hyperinsulinemia, thereby improving glucose toxicity compared with multiple injection insulin treatment. Among other concepts, metformin, pioglitazone, incretin-based drugs such as GLP-1 receptor agonists, sodium-glucose cotransporter inhibitors, and pramlintide can improve insulin resistance, either directly or indirectly. However, considering the current issues of high cost, side effects, limited efficacy, and their off-label status, these agents in people with T1D are not widely used in routine clinical care at present.

01 May 2025·Clinical Spine Surgery

Fusion Outcomes of GLP-1 Agonist Therapy in Multilevel Cervical Spinal Fusion

Article

Author: Levidy, Michael F ; Meister, Andrew S ; Bible, Jesse E ; Rowe, Nicholas D ; Vatsia, Sohrab K

Study Design::

Retrospective analysis.

Objective::

To evaluate the effects of GLP-1 agonist therapy upon the incidence of pseudarthrosis in patients undergoing multilevel cervical spinal fusion

Summary of Background Data::

The rising prevalence of obesity and diabetes mellitus has rendered the usage of glucagon-like peptide-1 receptor (GLP-1) agonists increasingly commonplace since their introduction in 2005. However, there is a dearth of evidence to suggest whether outcomes of multilevel cervical spinal fusion differ in patients treated with GLP-1 agonists. This study assesses rates of pseudarthrosis in patients who underwent multilevel cervical spine fusion with and without concurrent GLP-1 agonist therapy.

Methods::

The TriNetX, LLC Diamond Network database was queried utilizing CPT codes for patients undergoing both anterior and posterior multilevel cervical spinal fusion from 2005 to 2024. Patients prescribed liraglutide, pramlintide, tirzepatide, semaglutide, lixisenatide, or dulaglutide within 1 year of surgery were propensity matched to patients without GLP-1 agonist prescriptions. Cohort balancing was achieved categorically according to age at procedure, race, sex, and nicotine dependence. Cohort balancing was performed continuously to account for body mass index and hemoglobin A1C at the time of procedure. CPT diagnosis codes for pseudarthrosis after attempted fusion were concomitantly utilized to assess pseudarthrosis rates at 6-months, 1-year, and 2-years postoperatively using the Fisher exact test. Statistical significance was set at P<0.05.

Results::

In consideration of anterior multilevel cervical fusion, 1204 patients utilized GLP-1 agonist therapy, while 1204 patients did not use GLP-1 agonists. With respect to posterior multilevel cervical fusion, 1378 patients utilized GLP-1 agonist therapy, and 1378 patients did not have a GLP-1 agonist prescription. Anterior postoperative pseudarthrosis rates were significantly decreased in the GLP-1 agonist cohort versus the non-GLP-1 agonist cohort at 6-months (10.71% vs. 17.61%; P<0.001), 1-year (12.04% vs. 18.52%; P<0.001), and 2-years (12.87% vs. 19.19%; P<0.001). Posterior postoperative pseudarthrosis rates were also significantly decreased in the GLP-1 agonist cohort versus the non-GLP-1 agonist cohort at 6-months (13.21% vs. 22.28%; P<0.001), 1-year (14.37% vs. 24.45%; P<0.001), and 2-years (16.87% vs. 24.43%; P<0.001).

Conclusion::

Our findings demonstrate a statistically significant lower incidence of pseudarthrosis among patients treated with GLP-1 agonist therapy at all timepoints within this study—from 6-months to 2-years postoperatively, suggesting a potentially beneficial effect of GLP-1 agonist therapy in promoting fusion success in multilevel cervical spine surgery. Fundamentally, this aligns with the pharmacodynamic nature of GLP-1 agonists: as compounds that enhance osteoblastic activity and suppress osteoclastic activity, thereby facilitating bone formation and attenuating bone resorption. Further investigation into the mechanistic underpinnings of GLP-1 agonists’ effects on bone metabolism may pave the way for enhancing the success of cervical spine surgery.

News (Medical) associated with Pramlintide Acetate

05 Mar 2025

·www.echemi.com

AbbVie Invests $2.2 Billion to Develop Best-in-Class Obesity Drug

On March 3, 2025, AbbVie and Gubra announced a significant licensing agreement to collaboratively develop GUB014295, a promising long-acting amylin analogue aimed at treating obesity. This partnership marks AbbVie’s strategic entry into the obesity treatment market. As part of the agreement, AbbVie will oversee the global development and commercialization of GUB014295. Gubra is set to receive an upfront payment of $350 million and could earn up to $1.875 billion in milestone payments related to development, commercialization, and sales, along with tiered royalties on global net sales. Currently, GUB014295 is undergoing Phase I clinical trials. This innovative drug specifically activates amylin and calcitonin receptors, helping regulate appetite and promote satiety. Initial results from a single ascending dose trial indicated that GUB014295 was well-tolerated, with mild and transient gastrointestinal side effects. The drug exhibited favorable pharmacokinetic properties, with a half-life of 11 days, supporting weekly dosing. During the six-week trial, patients in the high-dose group (3.5 - 6.0 mg) experienced an average weight loss of about 3%, while those on placebo saw an increase of approximately 1%. A multiple ascending dose trial is currently underway, with mid-term results expected in the first half of 2025. Amylin, a 37-amino acid hormone, plays a critical role in glucose control and appetite regulation. Its potential as a therapeutic target for obesity is underscored by existing amylin analogues like Symlin, which has been on the market since 2005 for diabetes management. AbbVie’s investment in GUB014295 highlights the growing interest in effective obesity treatments, reflecting a broader trend in the pharmaceutical industry to address the rising global obesity epidemic. With this collaboration, AbbVie aims to leverage Gubra's innovation in the hope of bringing a groundbreaking obesity therapy to market.

Phase 1License out/inClinical Result

10 Jan 2025

·www.prnewswire.com

Iktos and Cube Biotech Announce Launch of Small Molecule AI Drug Discovery Collaboration

Partnership will leverage Iktos's AI-enabled drug discovery platform and Cube Biotech's advanced protein technologies to develop novel agonists of the Amylin Receptor PARIS and MONHEIM, Germany, Jan. 10, 2025 /PRNewswire/ -- Iktos, a leader in Artificial Intelligence (AI) and Robotics for drug design, and Cube Biotech, a pioneer in membrane protein production and purification technologies, today announced a strategic collaboration to discover novel small molecule agonists of the Amylin Receptor. The partnership combines Iktos' generative AI-driven drug discovery and robotic synthesis platform with Cube Biotech's advanced native membrane protein technology NativeMPTM, as well as their purification and biophysical assay expertise, to accelerate the development of breakthrough therapies. This paves the way for a joint collaborative offering directed towards pharmaceutical companies, combining the strengths of both platforms to undertake their most challenging drug discovery programs. Amylin receptor agonists hold significant promise for addressing unmet medical needs in cardiometabolic disorders, including obesity, diabetes, and metabolic dysfunction-associated steatotic hepatitis (MASH). The Amylin Receptor regulates appetite and satiety, making it a compelling target for obesity, which affects over one-third of the global population. Existing GLP-1 receptor agonist therapies like semaglutide or the peptide Amylin analogue Pramlintide have limited impact due to high costs, accessibility, and undesirable side effects. Orally administered novel small molecule agonists of the Amylin receptor could overcome these barriers, offering scalable and effective treatments and providing better management for the growing obesity epidemic and its comorbidities. However, the receptor's structural and biological complexity has long posed challenges for discovering viable low-molecular-weight modulators. "By tackling one of the most pressing unmet needs in cardiometabolic disorders, our partnership with Cube Biotech aims to discover improved treatments for patients affected by obesity, diabetes, and related conditions," said Yann Gaston-Mathé, Co-founder and CEO of Iktos. "We are excited to add the Amylin Receptor to our pipeline as this complex, yet promising target demands innovation at every stage. We see this collaboration as a foundation for future initiatives, extending the reach of our combined platform to address the most challenging membrane targets for the benefit of our pharma partners." Iktos has developed a cutting-edge 3D generative chemistry technology for structure-guided de novo design that natively accounts for protein flexibility during molecule optimization—a key advantage over models like AlphaFold, which can only be applied post-molecule generation. Cube Biotech has developed a world-leading protein production platform, based on NativeMP™ technology, which preserves the natural configuration of membrane proteins - a key advantage in accessing biologically active drug targets for testing. The company's native protein stabilization technology enhances the reliability and precision of functional assays, structural insights, and downstream applications. "Amylin Receptor is a challenging but highly promising target for metabolic disorders", said Dr. Barbara Maertens, Co-founder and COO of Cube Biotech. "Through our collaboration with Iktos, we aim to leverage our advanced protein stabilization and structural analysis technologies to validate and accelerate the discovery of novel small molecule agonists. Together, we are setting a new standard for efficiency and innovation in drug discovery." These integrated technologies endeavor to overcome longstanding inefficiencies in drug discovery, shortening timelines, improving success rates, and unlocking new possibilities for targeting complex and historically elusive membrane proteins, such as G-protein coupled receptors (GPCRs), membrane transporters, ion channels, and others. About Iktos Iktos is a leader in artificial intelligence and robotic solutions applied to research in medicinal chemistry and new drug design. Iktos' proprietary and innovative generative AI solution enables the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology through the SaaS software platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos has also developed Iktos Robotics, a unique AI-driven synthesis automation platform that dramatically accelerates the Design-Make-Test-Analyze cycle in drug discovery and is developing its own pipeline of drug candidates targeting oncology and auto-immune and inflammatory diseases. In March 2023, Iktos completed a 15.5M€ Series A financing round co-led by M Ventures and Debiopharm Innovation with contribution by Omnes Capital. In July 2024, Iktos announced the acquisition of Synsight, thereby complementing its Chemistry AI platform with a groundbreaking biology platform for the discovery of new drugs targeting Protein-Protein Interactions (PPI) and RNA-Protein Interactions (RPI). About Cube Biotech Cube Biotech is a leader in membrane protein production, purification, and characterization technologies. With proprietary copolymer-based solutions that maintain biological integrity in native-like protein states, Cube Biotech enables groundbreaking research in challenging drug targets, including membrane receptors, protein co-expressions, and even larger complexes. The company's expertise in assay development, biophysical characterization, and structural resolution supports efficient drug discovery workflows across the pharmaceutical and biotechnical industries. Additionally, an extensive purification resin and magnetic bead portfolio for affinity chromatography and efficient protein purification is manufactured in-house at high quality. For more information, visit . Media Contact: Eleonora Echegaray P: 35 823189279 E: [email protected] SOURCE Iktos WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Acquisition

21 Nov 2024

·www.businesswire.com

Versant Ventures Unveils Pep2Tango Therapeutics Inc.

POTOMAC, Md.--( BUSINESS WIRE )--Versant Ventures today announced the debut of Pep2Tango Therapeutics Inc., a startup focused on innovative, next-generation weight loss therapies. Proceeds from the significant, undisclosed round will support development of the company’s novel unimolecular tetra-receptor agonist peptides to treat obesity and related conditions. GLP-1-based therapies have proven efficacy in treating obesity and associated co-morbidities, but come with significant drawbacks. These include up to 40% of weight loss from muscle mass reduction, potentially leading to long-term side effects, especially in elderly patients. This limitation, in addition to tolerability issues, reduces the long-term utility of these agents. Pep2Tango’s lead drug candidates are engineered to overcome these drawbacks. They are unimolecular multi-receptor peptide agonists that target GLP-1, GIP, amylin and calcitonin receptors. This unique combination of targets in one molecule is truly differentiated with key advantages compared with first-generation drugs on the market and therapies currently in development. Preclinical studies of Pep2Tango’s molecules have demonstrated superior weight loss versus tirzepatide, primarily through selective fat mass loss with preservation of muscle mass, improved blood lipid profiles, better glycemic control, and beneficial effects on the liver. The company’s programs were developed by a deeply experienced team led by President, CEO and Chairperson Cristina Rondinone, Ph.D., and CSO Soumitra Ghosh, Ph.D. Dr. Rondinone previously was president of Cellarity, and SVP and head of cardiovascular, renal and metabolic diseases at AstraZeneca plc. Prior to that, she held roles of increasing responsibility in cardio-metabolic disease research and development at MedImmune Inc., Roche and Abbott Laboratories, where she led the research and development of multiple molecules that moved to clinical trials including Rezdiffra ™ , dorzagliatin and bentracimab. Dr. Ghosh is a co-founder of multiple biotech companies and served as executive director for research at Amylin Pharmaceuticals Inc., where he was involved in development efforts culminating in the approvals of Byetta ® , Symlin ® , Bydureon ® and Myalept ® . Dr. Ghosh also served as president of the Peptide Therapeutics Foundation. “We are delighted that Versant is backing Pep2Tango as we advance our programs towards clinical development,” said Dr. Rondinone. “There is a critical need to develop safe and highly efficacious drug therapies for obesity that preserve muscle mass and Pep2Tango’s approach should positively impact the lives of patients.” “We are thrilled to partner with the seasoned team of experts at Pep2Tango,” said Carlo Rizzuto, Ph.D., managing director at Versant and a Pep2Tango board member. “We are convinced that the company’s tetra-receptor agonists have best-in-category potential with respect to magnitude and quality of weight loss, as well as improving metabolic and cardiovascular health, that could redefine obesity treatment.” Pep2Tango Therapeutics is focused on CMC development activities to scale up drug candidate manufacturing and on running IND-enabling studies for a rapid transition to first-in-human clinical studies. An IND submission is expected in 2025. About Pep2Tango Therapeutics Inc. Pep2Tango Therapeutics is a biotechnology company founded in 2021 by seasoned pharmaceutical executives with a long track record of successful drug development. The company’s vision is to develop next generation peptide drugs that target unmet medical needs, including for metabolic, endocrine, CNS and cardiovascular disorders. Pep2Tango’s novel drug development approach for obesity focuses on unimolecular peptides that target multiple receptors, allowing for superior weight loss efficacy, muscle mass preservation, improved tolerability, and streamlined development and manufacturability. The company is backed by Versant Ventures. About Versant Ventures Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm’s emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $5.5 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and R&D expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 100 Versant companies have achieved successful acquisitions or IPOs. For more information, please visit www.versantventures.com .

Drug ApprovalIPO

100 Deals associated with Pramlintide Acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D05595	Pramlintide Acetate	A10BX05	DB01278

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 1	United States	AstraZeneca AB	16 Mar 2005
Diabetes Mellitus, Type 2	United States	AstraZeneca AB	16 Mar 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Insulin-Dependent, 2	Phase 3	United States	AstraZeneca PLC	01 Apr 2003
Obesity, Abdominal	Phase 2	United States	AstraZeneca PLC	01 Oct 2006
Obesity	Phase 2	United States	AstraZeneca PLC	01 Aug 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01841359 (CTgov)	Phase 4	Hypoglycemia \| Stomach Diseases	22	Pramlintide (Baseline (Prior to Pramlintide Treatment) Mixed Meal #1)	oivojyiaby(dzdktioaad) = krbmxdcyix sdcizaevpm (qnixfpoesw, 3255) View more	-	26 May 2022
				Pramlintide (Pramlintide - Mixed Meal #2)	oivojyiaby(dzdktioaad) = hgvtogkpmm sdcizaevpm (qnixfpoesw, 2770) View more
ENDO2021	Phase 2	Diabetes Mellitus, Type 1	18	XP-3924	amlhwrmctm(zaeyeqglho) = The incidence and severity of treatment emergent adverse events (e.g., injection site reactions, minimal nausea and vomiting) was comparable across all treatment arms with no drug-related serious adverse events vindggiufo (zpnbbspirn )	Positive	03 May 2021
				Regular Insulin (Humulin R) + Pramlintide (Symlin)
ADA2019	Not Applicable	Diabetes Mellitus, Type 1	24	BCPramIns	wktctgslym(spwycwbnmy) = Hypoglycemia during dosing visit days were balanced between the three treatment groups (4-3-3) dhujhkgpsg (znbtjhzjcd ) View more	-	01 Jun 2019
				PRAM+INS
SAT-LB028 (ENDO2019)	Not Applicable	Insulin Resistance	111	U-500 insulin only	hsxhegidvm(rvzydghknq) = imajejogij pvgxahzkyi (fwwuulmryk, 1.73) View more	Positive	30 Apr 2019
				U-500 insulin with pramlintide	hsxhegidvm(rvzydghknq) = tyxvlnhuwl pvgxahzkyi (fwwuulmryk, 1.24) View more
NCT00690235 (CTgov)	Phase 4	Diabetes Mellitus \| Schizoaffective disorder \| Schizophrenia ... View more	33	Pramlintide (Pramlintide)	kiwhfkpckj(rfoepwqzlv) = ftcidapuxl cloikskawd (efoffvamrm, 143.06) View more	-	16 Nov 2018
				Placebo (Placebo)	kiwhfkpckj(rfoepwqzlv) = hnawgenlja cloikskawd (efoffvamrm, 109.26) View more
NCT02500979 (CTgov)	Phase 1	Diabetes Mellitus, Type 1	34	Insulin (Placebo & Regular Insulin)	thtkenokae(hyqpzpayxz) = yaissxgvlj dvxwwrwfgr (batxmcvbin, 8.17) View more	-	02 Nov 2018
				Insulin+Pramlintide (Pramlintide & Regular Insulin)	thtkenokae(hyqpzpayxz) = gxxpegoqal dvxwwrwfgr (batxmcvbin, 8.17) View more
NCT02500979 (Pubmed \| Diabetes Care)	Phase 1	Diabetes Mellitus, Type 1	34	Pramlintide	jgrxwlcsid(qirkjpijvp) = kftmgjouen htsrycnmyc (hauftwvyay )	-	01 Nov 2018
				Placebo	jgrxwlcsid(qirkjpijvp) = dsjohpqrpa htsrycnmyc (hauftwvyay )
EASD2018	Not Applicable	-	-	BC Pram Ins	pestspzywn(dxrwgzngmj) = 0.45 [0.20; 1.05] jbgyrqdrvz (rijddhowds ) View more	Positive	02 Oct 2018
				Humulin
NCT00442767 (CTgov)	Phase 4	Diabetes Mellitus, Type 1 \| Hyperglycemia	8	Insulin (Rapid Acting Insulin Therapy - Before Meal)	gjvxvkmkfk(aiunbhosml) = rpsrzrubvj wcvzgcockv (jjoscskich, 116) View more	-	10 Jul 2018
				Insulin+Pramlintide (Pre-meal Pramlintide and Post-meal Insulin Therapy)	gjvxvkmkfk(aiunbhosml) = cbzjmkedtl wcvzgcockv (jjoscskich, 141) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis